跳至主要内容
临床试验/NCT01252914
NCT01252914已完成4 期

A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent

Glaukos Corporation1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2010年12月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
80
试验地点
1
主要终点
Mean diurnal Intraocular Pressure reduction of greater than or equal to 20% at month 12 vs. baseline

研究概览

简要总结

The purpose of this study is to assess the efficacy and safety of one iStent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.

详细描述

The study assesses the efficacy and safety of one iStent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Diagnosed with primary open-angle glaucoma (POAG)
  • •Subjects on two topical hypotensive medications

排除标准

  • •Traumatic, uveitic, neovascular, or angle closure glaucoma
  • •Fellow eye already enrolled

研究组 & 干预措施

One iStent Supra Stent and medication

Experimental

The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma

干预措施: iStent Supra Stent (Device)

结局指标

主要结局

Mean diurnal Intraocular Pressure reduction of greater than or equal to 20% at month 12 vs. baseline

时间窗: 12 months

次要结局

  • Mean diurnal Intraocular Pressure < 18 mmHg at month 12(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验